Compare Stocks

Fresenius SE (FSNUY) announced its intention to sell 13.4M shares in Fresenius Medical Care (FMS) through a placing to institutional investors by way of an accelerated bookbuild offering. The placing

Citi raised the firm’s price target on Fresenius SE (FSNUY) to EUR 59 from EUR 53 and keeps a Buy rating on the shares. Published first on TheFly – the

mAbxience, a majority-owned company of Fresenius (FSNUY) with partial ownership from Insud Pharma; and Sandoz (SDZNY) announced a licensing, development, manufacturing and commercialization agreement for an emicizumab biosimilar candidate. The

Fresenius Se (($FSNUY)) has held its Q2 earnings call. Read on for the main highlights of the call. Fresenius SE struck an upbeat tone on its latest earnings call, underscoring

Morgan Stanley analyst Aisyah Noor raised the firm’s price target on Fresenius SE (FSNUY) to EUR 52 from EUR 49 and keeps an Overweight rating on the shares. Published first

JPMorgan analyst David Adlington lowered the firm’s price target on Fresenius SE (FSNUY) to EUR 55.20 from EUR 56.60 and keeps an Overweight rating on the shares. Published first on

Deutsche Bank analyst Falko Friedrichs raised the firm’s price target on Fresenius SE (FSNUY) to EUR 56 from EUR 55 and keeps a Buy rating on the shares. Published first

Fresenius Se (($FSNUY)) has held its Q2 earnings call. Read on for the main highlights of the call. Fresenius SE’s latest earnings call struck an upbeat tone, with management highlighting

Fresenius Kabi, an operating company of Fresenius (FSNUY), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar developed by Dr. Reddy’s Laboratories, a biosimilar to Rituxan.

Fresenius Kabi announced that the U.S. Food and Drug Administration and the European Medicines Agency have accepted for review the Biologics License Application and Marketing Authorisation Application, respectively, for PB016,